by ODWAdmin | Sep 26, 2025 | Uncategorized
Proteolysis targeting chimeras (PROTACs) represent a revolutionary approach to targeted protein degradation, offering unprecedented opportunities to modulate previously “undruggable” targets in cancer and other diseases. As PROTAC research progresses from...
by ODWAdmin | Sep 25, 2025 | Uncategorized
Antibody-drug conjugates (ADCs) represent a paradigm shift in targeted cancer therapy, combining the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs through sophisticated linker chemistry. Despite remarkable clinical successes...
by Jason Heaviland | Sep 13, 2025 | Uncategorized
Your ELISA confirms the therapeutic enzyme is present. Your Western blot shows a band at the correct molecular weight. But here’s the critical question: is the enzyme actually functional? For mRNA-based enzyme replacement therapies targeting rare metabolic...
by Jason Heaviland | Sep 8, 2025 | Uncategorized
Phenotypic Screening and Target Deconvolution for Molecular Glue Discovery Molecular glue degraders represent a unique class of therapeutic compounds that modify E3 ligase substrate specificity to induce targeted protein degradation. Unlike PROTACs, which require...
by Jason Heaviland | Sep 8, 2025 | Uncategorized
The Assumption That Derails Programs The promise of mRNA therapeutics is elegant: deliver genetic instructions, let cells produce therapeutic proteins, and bypass traditional drug manufacturing. But there’s a critical gap between mRNA design and therapeutic...
